Tigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business
Key Highlights
- ➤Tigermed proposes privatizing controlled subsidiary Frontage Holdings (1521.HK)
- ➤Charles River (CRL) and Dr. Song Li to acquire Frontage’s overseas laboratory services
- ➤Tigermed will retain Frontage’s China laboratory services business
- ➤Overseas divestment covers preclinical research, laboratory testing, chemistry and CMC services
- ➤Transaction remains subject to conditions precedent and implementation requirements
Expert Statements
Dr. Xiaoping Ye, Co-founder and Chairman of Tigermed
“Our proposed participation in the privatization of Frontage, together with Charles River and Dr. Song Li, and the subsequent divestment of its overseas laboratory services business, represents an important strategic decision in advancing Tigermed's long-term development strategy.”
Dr. Xiaoping Ye, Co-founder and Chairman of Tigermed
“It also embodies our commitment to proactively transforming and optimizing our business portfolio.”
Dr. Xiaoping Ye, Co-founder and Chairman of Tigermed
“We believe these changes will create greater opportunities for business growth, deliver higher-quality services to our clients, generate sustainable long-term value for our shareholders, and ultimately contribute to bringing better healthcare products to patients.”
Tigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business PR Newswire
HANGZHOU, China, Nov. 10, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (Stock Codes: 300347.SZ / 3347.HK, hereinafter referred to as "Tigermed"), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, today announced its proposal to participate in the privatization of its controlled subsidiary Frontage Holdings Corporation (Stock Code: 1521.HK, hereinafter referred to as "Frontage"), through its wholly-owned subsidiary Hongkong Tigermed Co., Limited. Through a subsequent asset restructuring, Tigermed also proposes to divest Frontage's overseas laboratory services business to Charles River Laboratories International, Inc. (NYSE: CRL, hereinafter referred to as "Charles River") and Dr. Song Li, Chairman of the Board of Frontage, and his trusts while retaining Frontage's China business.
Get started
Create a free account to read the full story.